Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
We examined 14 patients with limbic encephalitis (LE) and suspected Hashimoto’s encephalopathy (HE) based on positive tests for anti-thyroid antibodies and anti-NH2-terminal of α-enolase (NAE) antibodies, a diagnostic marker for HE. The median age was 62.5 (20-83) years; 9 were women; 8 showed acute onset. Consciousness disturbance and seizures were commonly observed in the acute-onset group, whereas psychiatric symptoms and memory disturbance were common in the subacute-onset group. Tumours were not identified in any cases. All patients responded to immunotherapy or spontaneously remitted. Favourable therapeutic efficacy suggests that this LE can be considered a clinical subtype of HE and that anti-NAE antibodies may be a promising indicator of the need for immunotherapy. The patients’ sera reacted with the cytoplasm of hippocampal neurons. Immunoreactivity of the patients’ sera suggests that anti-NAE antibodies may contribute to the pathogenesis of the LE.
|